Nicolas Godin
Angel Investor
Paris, France
Nicolas Godin is a pre-seed investor in Paris focused on Health Care and Biotechnology. In addition to managing the company’s finances, Nicolas is responsible for Cardiologs’ operations and is a key voice on a variety of strategic and operational matters. Nicolas holds an MSc in Civil Engineering and an MBA from INSEAD, and started his career at PwC Transaction Services, working intensively on large European M&A deals. After anexperience at a VC fund in Paris, he joined the EdTech startup Coorpacademy, where he managed a Series B fundraising and transformed the company into a true SaaS business. Excited by the cross-functional nature of his role, Nicolas brings operational and financial excellence to Cardiologs.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Nicolas Godin invests in
Stages Nicolas Godin invests in
Countries Nicolas Godin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Biotechnology 2 (67%)
- Machine Learning 1 (33%)
- Predictive Analytics 1 (33%)
- Artificial Intelligence 1 (33%)
Country
- France 1 (33%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Surge is an immunological model capable of predicting postoperative infections. The company combines a single-cell assessment of the immune system before surgery with clinical data using a proprietary machine-learning algorithm. By analyzing the millions of immune cells in a small amount of blood, the platform can mimic surgical trauma in a testtube before surgery. | $2.6M / Pre-Seed / Sep 22, 2022 | ||
| Surge operates as a biotech company focused on optimizing treatment for patients undergoing surgery. | Pre-Seed / Sep 02, 2022 | ||
| Surge is an immunological model capable of predicting postoperative infections. The company combines a single-cell assessment of the immune system before surgery with clinical data using a proprietary machine-learning algorithm. By analyzing the millions of immune cells in a small amount of blood, the platform can mimic surgical trauma in a testtube before surgery. | Pre-Seed / Sep 01, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nicolas Godin invest in?
Nicolas Godin invests primarily in Health Care, Biotechnology and Machine Learning startups, most often at Pre-Seed stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Nicolas Godin?
Public channels for Nicolas Godin include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Nicolas Godin last invest?
The most recent investment recorded for Nicolas Godin closed in Sep 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
